List of Excipients in Branded Drug UP AND UP MINI NICOTINE

« Back to Dashboard

Generic Drugs Containing UP AND UP MINI NICOTINE

Company	Ingredient	NDC	Excipient
Target Corporation	nicotine polacrilex	11673-858	ACACIA
Target Corporation	nicotine polacrilex	11673-858	ACESULFAME POTASSIUM
Target Corporation	nicotine polacrilex	11673-858	BENZALDEHYDE
Target Corporation	nicotine polacrilex	11673-858	CALCIUM POLYCARBOPHIL
Target Corporation	nicotine polacrilex	11673-858	MAGNESIUM STEARATE
Target Corporation	nicotine polacrilex	11673-858	MANNITOL
Target Corporation	nicotine polacrilex	11673-858	POLACRILIN

What are the Most Frequently-Used Excipients in UP AND UP MINI NICOTINE?

# Of NDCs	Excipient
4	ACACIA
4	ACESULFAME POTASSIUM
3	BENZALDEHYDE
4	CALCIUM POLYCARBOPHIL
1	LIME OIL
4	MAGNESIUM STEARATE
1	MALTODEXTRIN

UP & UP Mini Nicotine: Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 26, 2026

Up & Up Mini Nicotine is a private-label nicotine-replacement lozenge sold through Target. Its commercial proposition is a compact, sugar-free oral dosage form that delivers nicotine polacrilex without the chewing profile of nicotine gum. The most attractive opportunities are faster dissolution, improved taste masking, moisture-stable packaging, lower-cost manufacturing, and differentiated dosing formats.

The product is regulated as an over-the-counter smoking-cessation medicine under the FDA nicotine-replacement framework. Its commercial exposure is primarily retail and formulation-based rather than dependent on a strong, product-specific patent estate.

What is Up & Up Mini Nicotine?

Up & Up Mini Nicotine is an OTC nicotine lozenge marketed under Target’s Up & Up private-label brand. Public product labeling identifies nicotine polacrilex as the active ingredient, generally in 2 mg and 4 mg strengths for smoking cessation.[1]

Attribute	Publicly associated product position
Brand	Up & Up
Retailer	Target
Dosage form	Mini nicotine lozenge
Active ingredient	Nicotine polacrilex
Typical strengths	2 mg and 4 mg nicotine-equivalent products
Route	Buccal/oral dissolution
Regulatory category	OTC nicotine-replacement therapy
Primary use	Temporary aid to stop smoking
Commercial channel	Mass retail, Target stores, Target.com
Sugar content	Typically sugar-free
Orange Book status	Generally not expected to have an Orange Book-listed product patent
Generic substitution	Less relevant than in prescription products because the product is OTC and private-label

The exact inactive-ingredient composition can vary by strength, flavor, supplier, and package revision. A current Drug Facts label should control any formulation or regulatory assessment.

What excipients are used in mini nicotine lozenges?

The likely excipient system combines a soluble or rapidly dispersible filler, a binder or matrix former, buffering agents, sweeteners, flavoring, and a lubricant. Publicly available labels for nicotine lozenges commonly identify excipients such as mannitol, calcium phosphate, sodium alginate, sodium bicarbonate, magnesium stearate, high-intensity sweeteners, and flavor systems.[1]

Functional role of the excipients

Excipient category	Likely function	Commercial relevance
Mannitol	Bulk filler, cooling mouthfeel, low hygroscopicity	Supports sugar-free positioning and acceptable taste
Calcium phosphate	Filler, compression aid, structural support	Can improve tablet hardness and lower cost
Sodium alginate	Binder, matrix former, dissolution modifier	Controls handling and oral texture
Sodium bicarbonate	Buffering agent	Supports nicotine release and taste control
Magnesium stearate	Lubricant	Enables tableting but can slow wetting if overused
Sucralose or acesulfame potassium	High-intensity sweetener	Masks nicotine bitterness
Mint or other flavor	Taste masking and product differentiation	Drives repeat use and line extensions
Sodium-containing salts	Buffering and ionic-strength control	Affect salivation, dissolution, and taste

The excipient strategy must balance four competing targets: rapid nicotine release, mechanical strength, low moisture uptake, and acceptable mouthfeel. Increasing binder or lubricant levels may improve manufacturing performance while slowing dissolution. Increasing buffer concentration can improve nicotine sensory performance but may add salinity or chalkiness.

How should the excipient system be optimized?

A robust development strategy would use a direct-compression formulation with controlled particle-size distributions and low-moisture processing. The mini format creates tighter weight and content-uniformity constraints than a conventional lozenge.

1. Improve taste masking

Nicotine has a bitter, alkaline, and irritant sensory profile. Taste masking should rely on a layered system rather than a single sweetener.

Potential approaches include:

• Combining mannitol’s cooling effect with mint or menthol flavor.
• Using sucralose with acesulfame potassium to reduce aftertaste.
• Adjusting bicarbonate and other buffers to reduce harshness.
• Applying a polymeric or lipid-based nicotine coating.
• Using ion-exchange or complexation technology where the dissolution profile remains compliant.
• Reducing exposed nicotine on the tablet surface through controlled granulation.

Taste masking is commercially important because cessation products are used repeatedly throughout the day. A lozenge that produces mouth irritation, bitterness, or excessive salivation can reduce adherence even if nicotine delivery is pharmacologically adequate.

2. Control dissolution time

A mini lozenge should dissolve quickly enough to provide convenient nicotine delivery but slowly enough to avoid an abrupt nicotine release and poor user experience.

The principal formulation levers are:

• Particle size of nicotine polacrilex.
• Compression force.
• Sodium alginate concentration.
• Binder grade and level.
• Lubricant concentration and mixing time.
• Tablet porosity.
• Buffer composition.
• Surface coating.

A practical target is a reproducible dissolution profile across the first several minutes of use, with limited batch-to-batch variation. The commercial risk is a tablet that behaves like an immediate-release sublingual tablet rather than a controlled-dissolution lozenge.

3. Improve moisture stability

Nicotine lozenges can be sensitive to humidity because hygroscopic excipients, flavor oils, and porous tablets can alter hardness and dissolution during storage.

The preferred excipient and packaging strategy is:

• Low-moisture mannitol and mineral filler grades.
• Minimal use of hygroscopic binders.
• Low residual moisture after granulation.
• Moisture-barrier blister packaging.
• Desiccant-supported bottles where unit-dose packaging is not used.
• Flavor systems compatible with the packaging barrier.
• Stability testing under accelerated and long-term conditions.

Packaging may offer greater practical protection than incremental excipient changes. A low-cost bottle with poor moisture ingress can erase the benefit of an optimized tablet formulation.

4. Improve manufacturability

A mini tablet increases the risk of weight variation, capping, sticking, and friability. The formulation should therefore be engineered around:

• Uniform powder flow.
• Narrow particle-size distribution.
• Adequate compactibility at low tablet weight.
• Controlled magnesium stearate addition.
• Low dust generation.
• Reliable ejection from the tablet press.
• Strong content uniformity for nicotine polacrilex.

Roller compaction can improve flow and density, but excessive densification may extend dissolution time. Wet granulation can improve uniformity but introduces water exposure and additional drying controls. Direct compression is commercially attractive if the active and excipient grades provide adequate flow and blend uniformity.

What commercial opportunities exist for Up & Up Mini Nicotine?

The product has several line-extension opportunities that do not require a fundamentally new active ingredient.

Product-extension opportunities

Opportunity	Development rationale	Commercial value
2 mg and 4 mg mini lozenges	Matches common nicotine-replacement dosing	Covers light and heavier smokers
Variety flavor packs	Reduces flavor fatigue	Supports repeat purchase
Unflavored or low-flavor version	Addresses users sensitive to mint	Expands consumer reach
Sugar-free, low-calorie positioning	Aligns with health-conscious use	Supports premium shelf positioning
Smaller-count trial pack	Lowers first-purchase barrier	Useful for online acquisition
Larger-count adherence pack	Reduces per-dose cost	Increases basket size
Individually wrapped lozenges	Improves portability and hygiene	Supports workplace and travel use
Pediatric-resistant packaging	Reduces accidental-ingestion risk	May improve household acceptability
Nicotine-combination kits	Pairs lozenges with patches	Supports stepped cessation programs
Fast-dissolving version	Differentiates from standard lozenges	May justify premium pricing

The most defensible near-term opportunity is a formulation and packaging upgrade rather than a new dosage strength. A compact lozenge with less bitterness, faster but controlled dissolution, and superior humidity protection could compete against national brands while preserving private-label pricing.

What FDA regulatory status applies to Up & Up Mini Nicotine?

Nicotine lozenges fall within the FDA’s OTC nicotine-replacement therapy framework. FDA regulations identify nicotine polacrilex as an active ingredient for smoking-cessation products, subject to conditions involving strength, labeling, directions, warnings, and dosage form.[2]

Regulatory considerations

The principal regulatory issues are:

1. Active ingredient identity. The product must use nicotine polacrilex meeting applicable quality specifications.
2. Strength declaration. The label must state the nicotine amount in the required form.
3. Drug Facts labeling. Smoking-cessation indications, directions, warnings, and age-related instructions must conform to FDA requirements.
4. Manufacturing controls. The product is subject to current good manufacturing practice requirements.
5. Dissolution and content uniformity. These become material when excipient changes affect release or dose consistency.
6. Packaging. Nicotine-containing products require controls against accidental pediatric exposure under applicable federal requirements.
7. Change management. Changes to flavor, binder, buffer, coating, or manufacturing process can require comparative quality and stability data.

An excipient change that does not alter the active ingredient may still require regulatory assessment if it affects dissolution, bioavailability, labeling, stability, or product performance.

What is the Orange Book status of Up & Up Mini Nicotine?

Up & Up Mini Nicotine is not generally expected to have a conventional Orange Book patent listing. The Orange Book primarily covers approved prescription drugs and certain approved nonprescription products submitted through an NDA pathway. An OTC monograph product typically does not depend on Orange Book-listed patents for market exclusivity.[3]

Are Paragraph IV challenges relevant?

Paragraph IV litigation is unlikely to be the principal competitive mechanism for this product. Paragraph IV certifications generally arise when an ANDA applicant challenges patents listed for an NDA product. A private-label OTC nicotine lozenge marketed under the monograph pathway is more likely to face:

• Competing OTC products.
• Retailer switching.
• Private-label sourcing changes.
• Formulation and manufacturing competition.
• Trademark and packaging disputes.
• Supplier qualification and capacity constraints.

No product-specific Paragraph IV challenge or Hatch-Waxman litigation can be reliably attributed to Up & Up Mini Nicotine based on the public product identity alone.

What patents protect nicotine lozenges?

Nicotine lozenge patent protection is usually divided into active-ingredient, formulation, manufacturing, delivery, and packaging categories. The basic use of nicotine polacrilex in an OTC lozenge is not likely to provide a durable exclusivity barrier by itself.

Patent categories with commercial relevance

Patent area	Potential claim scope	Relevance to Up & Up
Nicotine-resin complexes	Specific ion-exchange or resin systems	Could protect release and taste performance
Taste masking	Coatings, complexes, flavor systems	Relevant to differentiated mini formats
Fast-dissolving tablets	Porosity, excipient ratios, compression process	Potential product differentiation
Controlled-release lozenges	Matrix composition and dissolution profile	May create design-around risk
Manufacturing process	Granulation, blending, compression, coating	Protects process economics rather than brand identity
Packaging	Moisture barrier or child-resistant structures	Can reduce shelf-life and compliance risk
Combination therapy	Patch-plus-lozenge regimens	More relevant to branded cessation programs
Digital adherence systems	Connected packaging or dosing support	Limited relevance to the current physical product

A meaningful patent review would require the exact manufacturer, formulation, product strength, and manufacturing site. Without those identifiers, assigning specific patent numbers or expiration dates to Up & Up Mini Nicotine would not be accurate.

How strong is the patent estate for Up & Up Mini Nicotine?

The likely product-level patent estate is weak to moderate. The active ingredient and dosage form are established. Any defensible protection would more likely arise from a narrow formulation, manufacturing process, taste-masking architecture, or packaging design.

Patent-strength assessment

Factor	Assessment
Active ingredient novelty	Low
Dosage-form novelty	Low to moderate
Excipient-combination protection	Moderate if technically specific
Manufacturing-process protection	Moderate
Taste-masking protection	Moderate, but vulnerable to design-around
Packaging protection	Narrow and implementation-specific
Orange Book leverage	Low
OTC market barrier	Regulatory and supply-chain based
Generic-entry risk	High in practical terms
Private-label switching risk	High

The strongest commercial moat would be a combination of low-cost manufacturing, retailer distribution, reliable supply, and consumer familiarity. A single excipient patent would not normally prevent competing nicotine lozenges from entering the market through alternative excipient systems.

When does Up & Up Mini Nicotine lose exclusivity?

Up & Up Mini Nicotine does not have a clearly identifiable prescription-style exclusivity date. Its market access is based principally on OTC regulation, product compliance, and Target’s commercial control of the Up & Up brand.

The relevant exclusivity layers are:

Exclusivity layer	Likely position
New chemical entity exclusivity	Not applicable
Prescription NDA exclusivity	Not apparent
Pediatric exclusivity	Not apparent
Orange Book patent term	No confirmed product-specific listing
OTC monograph access	Available to compliant competitors
Trademark protection	Applies to Up & Up branding, not the nicotine formulation
Retail exclusivity	Controlled through Target’s sourcing and distribution
Supplier exclusivity	Contractual and potentially changeable

Competitors can generally market compliant nicotine lozenges without waiting for a branded patent expiration, subject to FDA requirements and applicable intellectual-property rights.

Which companies compete with Up & Up Mini Nicotine?

The competitive set includes national nicotine-replacement brands, other retailer brands, pharmacy generics, and alternative dosage forms.

Direct and indirect competitors

• Nicorette nicotine lozenges and mini lozenges.
• CVS Health nicotine lozenges.
• Walgreens nicotine lozenges.
• Walmart-associated nicotine-replacement products.
• Rite Aid and other pharmacy private-label products.
• Generic nicotine polacrilex lozenges.
• Nicotine gum.
• Nicotine patches.
• Nicotine pouches, where legally marketed and positioned for nicotine use rather than smoking cessation.

Nicorette has greater consumer recognition and a branded product-development platform. Up & Up can compete through lower price, Target traffic, multipack economics, and packaging simplicity. Patches compete on once-daily dosing, while lozenges compete on flexible, episodic dosing.

What revenue exposure exists for Target and suppliers?

Target does not generally disclose revenue for individual Up & Up SKUs. Product-level sales, gross margin, supplier identity, and unit volumes are therefore not publicly established.

The commercial economics are likely driven by:

• Retail price relative to Nicorette.
• Units per package.
• Repeat purchase frequency.
• Seasonal and promotional pricing.
• Store and online availability.
• Smoking-cessation demand.
• Private-label gross-margin targets.
• Manufacturing scale and packaging cost.
• Retailer negotiating leverage over contract manufacturers.

For suppliers, the product can be attractive because nicotine lozenges use established tableting technology and can be manufactured at scale. The principal operational risks are nicotine handling, content uniformity, moisture control, flavor consistency, and validated cleaning procedures.

What generic launch scenarios exist?

The most likely competitive-entry scenarios are commercial rather than litigation-driven.

Scenario 1: Price-led private-label competition

A pharmacy or mass retailer launches a comparable 2 mg or 4 mg nicotine mini lozenge at a lower price. The response would depend on Target’s shelf placement, online search ranking, and promotional strategy.

Scenario 2: Formulation-led competition

A competitor introduces a faster-dissolving or better-tasting lozenge. If the product achieves better adherence, it could take share despite a higher price.

Scenario 3: Packaging-led competition

A competitor uses individually wrapped, child-resistant, moisture-barrier packaging. This could improve portability and shelf stability without requiring a new active ingredient.

Scenario 4: Combination-therapy competition

A supplier markets a patch-plus-lozenge cessation kit. This could shift consumer purchases from standalone lozenges to bundled therapy.

Scenario 5: Non-combustible nicotine substitution

Nicotine pouches and other oral nicotine products may compete for adult nicotine consumers, although their regulatory status, claims, and positioning differ from smoking-cessation lozenges.

Key Takeaways

• Up & Up Mini Nicotine is a Target private-label nicotine polacrilex lozenge, generally associated with 2 mg and 4 mg strengths.
• The excipient system must optimize taste masking, dissolution, moisture stability, and mini-tablet manufacturability.
• Mannitol, mineral fillers, sodium alginate, bicarbonate buffers, sweeteners, flavoring, and magnesium stearate are commercially relevant excipient categories.
• The strongest product opportunities are improved taste, individually wrapped packaging, moisture protection, variety packs, and combination-therapy bundles.
• The product is likely regulated through the OTC nicotine-replacement framework rather than prescription NDA exclusivity.
• No conventional Orange Book or Paragraph IV strategy is apparent for the product.
• The likely patent estate is weak to moderate and would depend on narrow formulation, process, taste-masking, or packaging claims.
• Revenue by SKU and supplier identity are not publicly disclosed.
• Competitive risk is high because compliant OTC nicotine-lozenge competitors can enter without waiting for a branded patent expiration.

FAQs

Can Up & Up Mini Nicotine use a different sweetener system?

Yes. A reformulated product could use different high-intensity sweeteners, polyols, flavors, or taste-masking agents, subject to FDA compliance, stability, dissolution, and labeling requirements.

Does nicotine polacrilex require a proprietary excipient?

No. Nicotine polacrilex is an established active ingredient. The excipient system is selected to control taste, release, tablet strength, and manufacturability.

Could a mini nicotine lozenge receive patent protection?

Yes, but protection would likely require a technically specific formulation, dissolution profile, taste-masking system, manufacturing process, or packaging configuration. Broad claims to a nicotine lozenge are more vulnerable to prior-art challenges and design-around strategies.

Is a nicotine lozenge eligible for FDA 180-day generic exclusivity?

Not typically through the standard ANDA framework if the product is marketed under the OTC monograph pathway. The applicable route depends on the product’s regulatory basis and any relevant FDA application history.

Which excipient is most important for nicotine-lozenge performance?

No single excipient determines performance. The critical interaction is among the filler, binder or matrix former, buffer, sweetener, flavor system, lubricant, compression force, and packaging environment.

References

1. Target Corporation. (n.d.). Up & Up nicotine mini lozenges product labeling. Target product information and Drug Facts labeling.

2. U.S. Food and Drug Administration. (2024). Nicotine replacement therapy products. FDA Center for Drug Evaluation and Research.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. Electronic Code of Federal Regulations. (2024). 21 C.F.R. Part 341: Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use. U.S. Government Publishing Office.

5. U.S. Food and Drug Administration. (2024). Current good manufacturing practice requirements for finished pharmaceuticals, 21 C.F.R. Parts 210 and 211. FDA.